tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

LABP Stock Latest News

Landos Biopharma reports Q4 EPS (13c), consensus (19c)
The FlyLandos Biopharma reports Q4 EPS (13c), consensus (19c)
5d ago
LABP
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
Press ReleasesLandos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
5d ago
LABP
Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
Press ReleasesLandos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
28d ago
LABP
Landos announces acceptance of NX-13 abstract in UC treatment
The FlyLandos announces acceptance of NX-13 abstract in UC treatment
3M ago
LABP
Landos Biopharma announces abstract on NX-13 to be presented at ECCO
The FlyLandos Biopharma announces abstract on NX-13 to be presented at ECCO
3M ago
LABP
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
Press ReleasesLandos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
3M ago
LABP
Jefferies cuts Landos to Underperform with no major catalysts seen for 2 years
The FlyJefferies cuts Landos to Underperform with no major catalysts seen for 2 years
3M ago
LABP
Landos Biopharma downgraded to Underperform from Hold at Jefferies
The FlyLandos Biopharma downgraded to Underperform from Hold at Jefferies
3M ago
LABP
Landos Biopharma provides update on clinical development plans
The FlyLandos Biopharma provides update on clinical development plans
3M ago
LABP
Landos Biopharma announces $16.7M private placement financing
The FlyLandos Biopharma announces $16.7M private placement financing
3M ago
LABP
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
Press ReleasesLandos Biopharma Provides Comprehensive Update on Clinical Development Plans
3M ago
LABP
Landos Biopharma Announces $16.7 Million Private Placement Financing
Press ReleasesLandos Biopharma Announces $16.7 Million Private Placement Financing
3M ago
LABP
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
Press ReleasesLandos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
5M ago
LABP
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Press ReleasesLandos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
8M ago
LABP
3 ‘Strong Buy’ Small-Cap Stocks With Plenty of Upside
Stock Analysis & Ideas3 ‘Strong Buy’ Small-Cap Stocks With Plenty of Upside
1y ago
BRLT
DBTX
Landos Biopharma on Its Way to Commercialization
Stock Analysis & IdeasLandos Biopharma on Its Way to Commercialization
1y ago
LABP
Raymond James: These 3 Stocks Have Over 100% Upside on the Horizon
Stock Analysis & IdeasRaymond James: These 3 Stocks Have Over 100% Upside on the Horizon
2y ago
HAE
LABP
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.